6-K 1 tm2427663d1_6k.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2024

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Grifols, S.A.

TABLE OF CONTENTS

Item |  | Sequential Page Number
1. | Third Quarter 2024 Results release, dated November 7, 2024 |  | 4
2. | Q3 2023 Earnings Presentation |  | 8

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

| Grifols, S.A.
| By: | /s/ David I. Bell
|  | Name: | David I. Bell
|  | Title: | Authorized Signatory

Date: November 7, 2024

Third Quarter 2024 Results

Grifols Delivers Strong Third-Quarter Performance Led by Biopharma 12.1% Growth

| · | Revenue increased by 12.4% cc1 to EUR 1,793 million for the third quarter driven by Biopharma (+12.1% cc), with a year-to-date revenue of EUR 5,237 million, an increase of 9.1% cc

| · | Adjusted EBITDA in the third quarter grew by 26.7% cc to EUR 462 million (25.8% margin), bringing year-to-date EBITDA to EUR 1,253 million (23.9% margin) driven by product mix, lower cost per liter and operational leverage

| · | Free Cash Flow2 increased to EUR 127 million in the quarter primarily driven by improved working capital management

| · | Net profit was EUR 52 million (EUR 88 million YTD), impacted by non-recurring financial and tax expenses associated with the debt reduction following the sale of the 20% of SRAAS. Net income excluding one-offs amounted to EUR 264 million for the first nine months of the year

| · | Leverage ratio3 declined sequentially to 5.1x from 6.8x in Q1’24

| · | Reaffirmed guidance for full year 2024

Barcelona, Spain – November 7, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, reported strong third quarter results, delivering sequential improvement across key metrics.

Nacho Abia, Chief Executive Officer, commented, “I am proud of the strong third quarter performance delivered by the entire Grifols team. We have successfully built growth momentum, maintained disciplined cost control and advanced our continuous improvement initiatives. With this work underway, and our strong fundamentals, we continue to make progress on achieving our 2024 targets.”

Rahul Srinivasan, Chief Financial Officer, said “This record-breaking quarter stands as a testament to the passion and commitment of our entire team at Grifols towards our mission of improving patients' lives globally and supporting our donors. We remain firmly focused on our ongoing priorities of deleveraging and free cash flow generation.”

Business Segment Performance

In the third quarter of 2024, total revenue reached EUR 1,793 million, a year-over-year increase of 12.4% cc (12.2% on a reported basis). This brought year-to-date revenue to EUR 5,237 million, up 9.1% cc (8.6% reported), driven by strength in Biopharma.

Note: For comparative purposes with YTD Q3’24, the financial statements for Q3'23 and Q4’23 have been re-expressed according to the Inside Information released on July 30, 2024, and further disclosed in accordance with Note 2(d) of the Consolidated Interim Financial Statements for H1'24

1 Operating or constant currency (cc) excludes changes rate variations reported in the period

2 Excluding SRAAS transaction

3 Defined as per the Credit Agreement

Page 1 of 4

Biopharma revenue grew by 12.1% cc (12.1% reported) in Q3’24 to EUR 1,533 million across key geographies, supported by strong demand for key proteins, particularly immunoglobins (+16.6% cc) and albumin (+11.7% cc) in the U.S. and international markets. Year-to-date revenue grew by 9.9% cc (9.6% reported) to EUR 4,455 million.

The immunoglobin franchise grew by 14.3% cc in the first nine months of the year as a result of successful launches in Europe and strong performance in the U.S. of subcutaneous immunoglobulin (SCIG), which increased by 51.8% cc. Albumin grew by 10.3% cc year-to-date, mainly driven by higher demand in China. Additionally, Alpha-1 and specialty proteins grew 1.3% cc year-to-date, driven by higher demand of Rabies in the US, while Alpha-1’s saw a paced recovery in the third quarter following the strategic transition of our specialty pharma distributor in the U.S.

Diagnostic sales were up 1.7% cc (+0% reported) on a like-for-like basis4 to EUR 479 million in the first nine months of the year, increasing 1.3% cc (+0% reported) in the third quarter. Improved performance was mainly driven by Blood Typing Solutions, up 13.7% cc year-to-date (+11.4% cc in the quarter), as well as our Nucleic Acid Testing Donor Screening (NAT) business, which grew by 3.5% cc in the third quarter.

Plasma supply continues to be managed efficiently, with cost per liter (CPL) declining modestly in the third quarter, further extending the significant drop since peak cost in July 2022. The outlook for plasma costs remains positive, with opportunities for further cost reductions stemming from continuous improvement initiatives aimed at increasing efficiencies.

Financial Performance and Leverage

Adjusted EBITDA in the third quarter was EUR 462 million with a 25.8% margin, an increase of 26.7% cc (24.6% reported) compared to the third quarter of 2023. Year-to-date, adjusted EBITDA was EUR 1,253 million, an increase of 25.0% cc (23.1% reported). This performance reflects an enhanced product mix, gross margin improvement following the reducing of cost per liter reported over the last quarters, and strong commercial execution and operational leverage.

Reported EBITDA for the third quarter was EUR 425 million and EUR 1,149 million in the first nine months of 2024, with margins of 23.7% and 21.9%, respectively. In the third quarter, reported EBITDA mainly included close to EUR 30 million of non-recurring transaction and restructuring costs and EUR 5 million from the Biotest Next Level (BNL) project5.

Reported net profit stands at EUR 88 million year-to-date, an increase of EUR 102 million year-over-year, driven by a strong third quarter total of EUR 52 million. Net profit was impacted by certain non-recurring financial and tax expenses associated with the Company’s efforts to reduce debt and the SRAAS transaction. Excluding these items, the Company’s net profit amounted to EUR 264 million in the first nine months of the year.

4 Excluding the EUR 19 million commercial true-up in Immunoassay Donor Screening (formerly Recombinant proteins) from the first quarter of 2023. Including this amount, Diagnostic performance stands at -2.1% cc (-3.8% reported) on a year-to-date basis vs. PY

5 Next Level (BNL) is a one-off project aimed to increase production capacity in Dreieich, Germany

Page 2 of 4

Free Cash Flow6 increased to EUR 127 million for the third quarter, reflecting sequential improvement compared to the EUR 253 million deficit in the first quarter and EUR 57 million in the second quarter. Third quarter Free Cash Flow was mainly driven by improved working capital management.

As of September 30, 2024, Grifols had a net financial debt as per the Credit Facility of EUR 8,128 million. This amount does not include the impact of the financial obligations related to leasing, primarily of plasma centers (IFRS 16) – the related impact is EUR 1,080 million. Therefore, net financial debt on the Balance Sheet stood at EUR 9,208 million. Liquidity position stands at EUR 704 million.

Deleveraging remains a top priority, with the leverage ratio standing at 5.1x7 for the quarter, down from 5.5x in the second quarter of 2024 and 6.8x in the first quarter. The company remains focused on strengthening its financial profile, as evidenced by the allocation of all proceeds from the
EUR 1.6 billion SRAAS asset sale to reduce the 2025 Senior Secured Notes and 2027 Term Loan B’s in the third quarter.

Alternative Performance Measures (APMs)

This document contains the following Alternative Performance Measures (APMs): Consolidated EBITDA Reported, Consolidated EBITDA Adjusted, Leverage Ratio as per the Credit Facility, Net Debt as per the Credit Facility, Free Cash Flow, Working Capital, and non-recurring items. For further details on the definition, explanation on the use, and reconciliation of APMs, please see the Appendix of the Presentation as well as the “Alternative Performance Measures” document from our website www.grifols.com/en/investors.

CONFERENCE CALL

Grifols will host a conference call today, Thursday, November 7, 2024, at 6:30pm CET / 12:30pm EST to provide a Business Update and its Third Quarter 2024 Financial Results. To view and listen to the webcast and view the presentation, click on Grifols Q3’24 Results or visit the website www.grifols.com/en/investors. Participants are advised to register in advance of the conference call.

INVESTORS:

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

6 Excluding SRAAS transaction

7 Defined as per the Credit Agreement

Page 3 of 4

MEDIA CONTACTS:

Grifols Press Office media@grifols.com / Tel. +34 93 571 00 02
Spain Duomo Comunicación Tel.: +34 91 311 92 89 – +34 91 311 92 90 Raquel Lumbreras (M. +34 659 572 185) Raquel_lumbreras@duomocomunicacion.com Borja Gómez (M. +34 650 402 225) Borja_gomez@duomocomunicacion.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com

Forward-Looking Statements

This note contains forward-looking information and statements about Grifols based on current assumptions and forecast made by Grifols management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expected”, “potential”, “estimates” and similar expressions.

Although Grifols believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Grifols.

Page 4 of 4

- 1 - Q3 2024 Results Q3 2024 Results November 7, 2024

- 2 - Q3 2024 Results Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisio ns of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated m ark et, and repealing Directive 2003/71/EC, the Spanish Securities Market and Investment Services Law (Law 6/2023, of 17 March, as amended and restated from time to time), Royal Decree 814/2023, of Novem ber 8, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, no r a request for any vote or approval in any other jurisdiction. This information has not been audited. Forward - Looking Statements This presentation contains forward - looking information and statements about Grifols based on current assumptions and forecast ma de by Grifols management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergi es, products and services, and statements regarding future performance. Forward - looking statements are statements that are not historical facts and are generally identified by the words “expected”, “potent ial ”, “estimates” and similar expressions. Although Grifols believes that the expectations reflected in such forward - looking statements are reasonable, various known and u nknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given her e. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company a ssu mes no liability whatsoever to update these forward - looking statements or conform them to future events or developments. Forward - looking statements are not guarantees of future performance. They have no t been reviewed by the auditors of Grifols. Alternative Performance Measures (APMs) This document and any related conference call or webcast (including a Q&A session) contain, in addition to the financial info rma tion prepared in accordance with IFRS, alternative performance measures (‘APMs’) as defined in the guidelines issued by the European Securities and Markets Authority (‘ESMA’) on October 5, 2015. APMs are used by Grifols’ management to evaluate the group’s financial performance, cash flows or financial position in making operational and strategic decisions for the group and therefore are useful information for inves tor s and other stakeholders. Certain key APMs form part of executive directors, management and employees’ remuneration targets. APMs are prepared on a consistent basis for the periods presented in this document. They should be considered in addition to IFR S measurements, may differ to definitions given by regulatory bodies relevant to the group and to similarly titled measures presented by other companies. They have not been audited, reviewed or verified by the ext ernal auditor of Grifols. For further details on the definition, explanation on the use, and reconciliation of APMs, please see the appendix as well as the “Alternative performance measures” document from our websi te www.grifols.com/en/investors . Basis of Presentation For comparative purposes with YTD Q3'24, the financial statements for Q3’23 and Q4’23 have been re - expressed according to the In side Information released on July 30, 2024, and further disclosed in accordance with Note 2(d) of the Consolidated Interim Financial Statements for H1’24.

- 3 - Q3 2024 Results 01 02 03 04 Introductory Remarks Business Performance Financials Final remarks Annex 05 Agenda Nacho Abia Chief Executive Officer (CEO) Rahul Srinivasan Chief Financial Officer (CFO)

- 4 - Q3 2024 Results Nacho Abia Chief Executive Officer (CEO) Continued Delivery of Sequentially Strong Quarterly Performance Led by Biopharma

- 5 - Q3 2024 Results Accelerating Performance and Executing on Strategy Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. 1 Excluding SRAAS transaction; 2 Defined as per the Credit Agreement; refer to Annex; 2 Corporate Sustainability Assessment (CSA). REVENUE €1,793m EBITDA ADJ. €462m Margin 25.8% FREE CASH FLOW 1 €127m LEVERAGE RATIO 2 5.1x Q3 Figures Variation vs. PY (% at cc) Introductory Remarks Business Performance Financials Final remarks Annex • Solid growth across all Business Units and core markets • Margin expansion driven by product mix, lower Cost per liter and operational leverage • Liquidity EUR 704m • Reiterating FY24 guidance • Efficient management of supply • Cost Per Liter continued to decline • Executing on initiatives to increase plasma and manufacturing efficiencies • On track to achieve 2024 milestones • Fibrinogen ’s regulatory progress started in EU and on track in the U.S. • GigaGen awarded U.S. BARDA contract to develop its recombinant polyclonal antibody therapeutic platform • Advancing on our sustainability agenda • Achieved our highest - ever score in the 2024 S&P Global CSA 2 • Awarded Gold Medal by EcoVadis Financials Plasma Innovation Sustainability +12.4% +26.7% +€97m 6.8x Q1’24

- 6 - Q3 2024 Results Delivering Sequential Improvement in Key Metrics €(253)m €57m €127m Q1'24 Q2'24 Q3'24 6.8 x 5.5 x 5.1 x Q1'24 Q2'24 Q3'24 5.5% 9.3% 12.4% Q1'24 Q2'24 Q3'24 Quarterly Adj. EBITDA Margin LTM Adj. EBITDA Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. 1 Excluding SRAAS transaction proceeds; 2 Defined as per the Credit Agreement Introductory Remarks Business Performance Financials Final remarks Annex Revenue growth (at cc) EBITDA Adjusted € 1,514 m € 1,605 m € 1,697 m 21.6% 24.2% 25.8% 18% 20% 22% 24% 26% 28% 1300 1350 1400 1450 1500 1550 1600 1650 1700 Q1'24 Q2'24 Q3'24 Free Cash Flow 1 Leverage Ratio 2

- 7 - Q3 2024 Results Continued Strong Revenue Growth Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. 1 Underlying growth excluding one - off in Q1’23 revenues related to a €19m commercial true - up in Diagnostic; 2 Blood Typing Solutions; 3 Immunoassay Donor Screening (IDS), previously named Recombinant Proteins 4,822 5,260 11 45 23 1 2 3 4 5 6 7 5,237 YTD Q3’23 Biopharma Diagnostic Bio Supplies and others YTD Q3’24 CC FX YTD Q3’24 404 +9.1% +8.6% • Growth across core geographies • Positive product mix • Strong growth of albumin in China • Alpha - 1 trend improving Revenues (in million EUR) Biopharma +12.1% Q3’24 • BTS 2 driving growth at double - digits • Strong underlying NAT business • IDS 3 one - off in Q1’23 impacting YTD growth Diagnostic +1.3% 1 Q3’24 +9.9% YTD Q3’24 +1.7% YTD Q3’24 Introductory Remarks Business Performance Financials Final remarks Annex

- 8 - Q3 2024 Results Immunoglobulin Leads Biopharma’s Double - Digit Growth Introductory Remarks Business Performance Financials Final remarks Annex Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. Biopharma Q1’24 Q2’24 Q3’24 8.9% 9.4% 12.1% +9.9% YTD • IVIG (+13% YTD) strong demand driven by the U.S. and international markets • SCIG (+52% YTD) continued strong momentum led by the U.S. and EU recent launches • Alpha - 1 paced recovery following the specialty pharma distributor transition in the U.S. • Rabies ’ higher demand in the U.S. • Higher demand in China • Competitive market dynamics in certain markets +12.5% +13.7% +16.6% +7.1% +11.9% +11.7% +4.4% - 4.1% +3.8% Immunoglobulin +14.3% YTD Albumin +10.3% YTD Alpha - 1 and specialty proteins +1.3% YTD Protein Strong growth driven by key proteins (Revenue growth at cc) Biopharma

- 9 - Q3 2024 Results Driving Operational and Efficiency Improvements Introductory Remarks Business Performance Financials Final remarks Annex Well - invested to further capture growth with 405 plasma centers across the U.S., Europe , Canada and Egypt 01 Maximizing IG yields with nomogram deployment and manufacturing processes 03 Operational excellence in all business areas 04 Focus on donor experience to bolster donor satisfaction 05 Leveraging on new technologies and process efficiencies to further expand market share 02 Driving Commercial Performance Improving Operational Effectiveness Increasing momentum in U.S. and sustained EU growth • Europe driving double - digit growth Life cycle management and new product development • Xembify ® bi - weekly dosing FDA approval in July’24 • Alpha - 1 AT - 15% SC ph.1/2 first patient enrolled • Fibrinogen EU MAA submitted and on track for BLA U.S. Building capabilities • Building skills and new capabilities in the U.S. commercial team • Xembify ® accelerating with 8 EU launches in 2024 • Improved pull - through trends on IG brands • Moderately gaining IG market share • Reinforcing value proposition for Alpha - 1 patients Strengthening product offering Biopharma

- 10 - Q3 2024 Results On Track to Accomplish 2024 Innovation Milestones Introductory Remarks Business Performance Financials Final remarks Annex Milestone Alpha - 1 AT 15% SC Phase 1/2 Cohort 2 Tx 1: First patient enrolled PRECIOSA Last Patient Out – LPLV OSIG in DED – Start of GLP Preclinical studies Yimmugo BLA FDA approval Xembify ® bi - weekly dosing FDA approval GIGA2339 in HBV Phase 1 IND submission PRECIOSA topline results Gamunex in bags conformance lots production Fibrinogen Congenital & Acquired Deficiency MAA/BLA submission H1 H1 H1 H1 H2 H2 H2 H2 H2 Status Completed On track • Awarded a contract to develop a recombinant polyclonal therapeutic for two proteins targeting: − All 7 serotypes of Botulinum neurotoxins ( BoNTs ) − Second biothreat to be determined at a later time GigaGen platform further demonstrated by the U.S. BARDA • To support the creation, manufacturing and initial clinical development • Contract valued of up to $135 million spread over 6 years 1 The MAA follows a Decentralized Procedure (DCP) with the Reference Member State Germany (PEI) and the Concerned Member States A ustria (AGES) and Spain (AEMPS) Biopharma MAA submitted 1 FDA BLA on track

- 11 - Q3 2024 Results Strengthening Leadership in Transfusion Medicine Diagnostic Introductory Remarks Business Performance Financials Final remarks Annex Business segment Secure leadership in the IVD Transfusion Medicine segment 1 Become an innovative, sizable and specialized player Clinical Diagnostics Leverage new testing platforms to enter Clinical Diagnostics segment 2 Transfusion Medicine Growing business seizing to become the leading player Blood Typing Solutions Stabilized business prepared for steady growth Donor Screening YTD Q3’24 Performance • Double - digit growth in key countries • Eflexis instrument gains further traction • Secured tenders in key markets • Blood donations volume stable in U.S. • I nroads in the tissue and organ testing market segment • Secured tenders in growing markets Strategic short - term levers • Manage Procleix Panther Life - Cycle • Retain strategic accounts • Developing new immunoassay technology for blood and plasma screening • Execute on commercial plan • Strengthen presence in core markets • Continue increasing profitability • Developing next - gen BTS instruments to further boost growth Premium Solutions Support Biopharma testing programs & new drug development Create further synergies with Biopharma 3

- 12 - Q3 2024 Results Rahul Srinivasan Chief Financial Officer (CFO) Clear Business Momentum and Strengthening Financial Profile

- 13 - Q3 2024 Results Introductory Remarks Business Performance Financials Final remarks Annex CFO First Impressions Mission - Focused Organization committed to mission of improving patients’ lives globally and serve donors Strong Foundation, A Market Leading Position and Scale Benefiting from the bold and visionary actions from the past Highly Attractive Business Fundamentals Strong prospects with diminishing extraordinary growth capex headwinds Financial Discipline Analytical rigor, risk management and cost and capital allocation discipline; continuing relentless focus on deleveraging and improving free cash flow generation Upside Potential Driving continuous improvement and operational excellence Communication A significant communication and engagement opportunity with all stakeholders

- 14 - Q3 2024 Results Q3 & YTD’24: A Record EBITDA Adj. Quarter, Strong Growth Across the Board Note: All figures are presented on a consolidated basis (including Biotest). When specified, figures presented at currency (c c), excluding exchange rate fluctuations over the period. See annexes for reconciliations. 1 Excluding SRAAS transaction; 2 Defined as per the Credit Agreement; 3 Pro - forma for €1.3bn senior secured notes refinancing senior unsecured notes maturing in 2025 Introductory Remarks Business Performance Financials Final remarks Annex Var vs. PY Reported Var vs. PY Reported +9.1% cc 5,237 +12.4% cc 1,793 REVENUE +14.5% cc 2,028 +16.6% cc 727 GROSS PROFIT +150bps 38.7% +110bps 40.5% Margin +25.0% cc 1,253 +26.7% cc 462 EBITDA ADJ. +270bps 23.9% +260bps 25.8% Margin +131.0% 233 +24.5% 119 PROFIT BEFORE TAX n/a 88 n/a 52 NET RESULT +144 (69) +97 127 FREE CASH FLOW 1 6.8x (Q1’24) 5.1x - - Total net leverage ratio LEVERAGE RATIO 2 4.5x (Q1’24) 3 3.1x - - Net secured leverage ratio Q3 2024 YTD 2024 (in million EUR except %)

- 15 - Q3 2024 Results Business momentum, operational excellence and operational leverage being key drivers • Volume growth • Further Cost per Liter decline • Plasma and Manufacturing yields improvement • Operational leverage Significant Growth in EBITDA and Margin Vs. a Record 2023 Introductory Remarks Business Performance Financials Final remarks Annex EBITDA Adjusted (in million EUR) Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. 357 425 Q3'23 Q3'24 One-offs EBITDA Reported 371 462 25.8% 23.2% Quarter Reported +260bps +26.7% 869 1,149 YTD Q3'23 YTD Q3'24 1,018 1,253 23.9% 21.2% Year - to - date +270bps +25.0%

- 16 - Q3 2024 Results 24% 24% 29% 25% 24% 23% 8.0% 13.0% 18.0% 23.0% 28.0% 0 400 800 1200 1600 2000 2019 2020 2021 2022 2023 LTM Q3'24 Opex % revenues Robust Rebound in EBITDA Adjusted Margin and Notable Operational Leverage Momentum Introductory Remarks Business Performance Financials Final remarks Annex 28.6% 27.4% 20.6% 20.2% 22.2% 24.2% -30.0% 0 500 1,000 1,500 2,000 2019 2020 2021 2022 2023 LTM Q3'24 EBITDA Adjusted EBITDA Adjusted Margin EBITDA Adjusted 1 (in million EUR except %) Operational Expenses 2 (in million EUR) Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. Figures for 2022 have been re - expressed according to the Insi de Information released on July 30, 2024 1 In 2019 and 2020, it corresponds to Underlying EBITDA reported at that time, which also considered certain one - off adjustments; 2 Opex excludes one - offs for the period FY22 - Q3’24, as consistently reported in annexes

- 17 - Q3 2024 Results YTD Q3’24 Continued Focus on Free Cash Flow is Yielding Results Introductory Remarks Business Performance Financials Final remarks Annex d Q3’24 Q2'24 Q1'24 1,253 462 441 350 EBITDA Adjusted (74) 59 (3) (130) Inventories (109) (19) 64 (154) Receivables (15) (62) 103 (56) Payables (198) (23) 164 (339) Net working capital (132) (51) (43) (38) CAPEX (96) (33) (41) (22) IT and R&D (95) (32) (59) (4) Taxes (395) (55) (233) (106) Interests (84) 15 (33) (66) Others 253 282 196 (225) Free Cash Flow before extraordinary items (256) (114) (119) (23) Extraordinary Growth CAPEX (66) (41) (20) (5) Transaction and restructuring costs (69) 127 57 (253) Free Cash Flow EBITDA Adjusted to Free Cash Flow reconciliation (in million EUR) Operating Cash Flow improvement fully offsetting extraordinary growth CAPEX • Working capital management focus • Disciplined approach to CAPEX, IT and R&D expenses • Interest expenses declined due to timing of coupon payments • ImmunoTek payments in FY24 • Transaction and restructuring costs: linked to Operational Improvement Plan − Liquidity EUR 704m 5 1 2 3 4 5 1 2 3 4 Note: All figures are presented on a consolidated basis (including Biotest). The EBITDA Adjusted to Free Cash Flow reconcilia tio n above excludes the SRAAS transaction. See annexes for reconciliations.

- 18 - Q3 2024 Results 7% 6% 6% 5% 3% 7% (incl. extraordinary) 3% 0% 1% 2% 3% 4% 5% 6% 7% 8% 0 100 200 300 400 500 2019 2020 2021 2022 2023 LTM Q3'24 Extraordinary CAPEX (primarily ImmunoTek) Growth CAPEX Maintenance CAPEX Diminishing Extraordinary Growth Capex Impact and Improving Inventory Management Introductory Remarks Business Performance Financials Final remarks Annex CAPEX Investments (in million EUR except %) Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See annexes for reconciliations. Figures for 2022 have been re - expressed according to the Inside Information released on July 30, 2024 1 Stock turnover in days calculated as inventory / COGS LTM 310 237 278 307 309 295 0% 5000% 10000% 15000% 20000% 25000% 30000% 35000% 0 1,000 2,000 3,000 4,000 2019 2020 2021 2022 2023 LTM Q3'24 Inventory (in million EUR) Inventory turnover (in days) Inventory 1

- 19 - Q3 2024 Results Strengthening our Financial Profile Introductory Remarks Business Performance Financials Final remarks Annex (million EUR) Sources 1,560 SRAAS Proceeds ~1,560 Total Sources (million EUR) Uses 392 EUR Term Loans Pro Rata reduction 673 EUR Term Loans Pro Rata reduction 495 Repayment Feb. 2025 Senior Secured Bond ~1,560 Total Uses Achieving FY24 Free Cash Flow guidance 01 Continued deleveraging focus 02 Extension of RCF underway 03 Used SRAAS sale proceeds 1 to reduce bonds and term loans (as of Q3 2024, in million EUR) Near - term priorities Terming out funded Senior Secured debt maturing in 2025 04 1 Net of transaction costs

- 20 - Q3 2024 Results Nacho Abia Chief Executive Officer (CEO) Final Remarks Setting the Course for Long - Term Success

- 21 - Q3 2024 Results Strengthened Executive Leadership with new CFO Rahul Srinivasan as key addition Strong Q3’24 results and no changes to FY24 guidance , reiterating solid fundamentals Reiterate strong commitment to cash flow generation and deleveraging priorities Plasma industry growth momentum driven by robust underlying demand in U.S. and EU Further enhancing operations and increasing efficiencies Accelerating R&D pipeline to strengthen product offering , add new indications and launch new products to the market 01 02 03 04 05 06 Setting the Course for Long - Term Success

- 22 - Q3 2024 Results ANNEX

- 23 - Q3 2024 Results Revenue | Q3 2024 Q3 2024 Q3 2023 In thousands of euros Reported At cc* Revenue by Business Unit 1,792,956 1,597,481 12.2% 12.4% Biopharma 1,532,745 1,367,663 12.1% 12.1% Diagnostic 156,292 156,283 0.0% 1.3% Bio Supplies 53,698 36,056 48.9% 48.7% Others & intersegments 50,221 37,479 34.0% 34.2% Revenue by Country 1,792,956 1,597,481 12.2% 12.4% US + CANADA 1,044,035 970,208 7.6% 7.2% EU 359,448 289,423 24.2% 24.2% ROW 389,474 337,850 15.3% 17.0% * Constant currency (cc) excludes exchange rate fluctuations over the period. Grifols Grifols Grifols % vs PY

- 24 - Q3 2024 Results Revenue | 2024 YTD 2024 YTD 2023 YTD In thousands of euros Reported At cc* Revenue by Business Unit 5,236,568 4,822,427 8.6% 9.1% Biopharma 4,455,100 4,065,878 9.6% 9.9% Diagnostic 478,835 497,772 (3.8%) (2.1%) Bio Supplies 163,261 118,670 37.6% 37.5% Others & intersegments 139,371 140,106 (0.5%) (0.0%) Revenue by Country 5,236,568 4,822,427 8.6% 9.1% US + CANADA 3,007,232 2,893,072 3.9% 4.2% EU 1,109,757 916,955 21.0% 21.0% ROW 1,119,579 1,012,400 10.6% 12.3% * Constant currency (cc) excludes exchange rate fluctuations over the period. Grifols Grifols Combined Grifols % vs PY

- 25 - Q3 2024 Results P&L | Q3 2024 In thousands of euros Reported One-offs Reported excl. One-offs Reported One-offs Reported excl. One-offs Reported Reported excl. One-offs Net Revenue 1,792,956 - 1,792,956 1,597,481 1,597,481 12.2% 12.2% Cost of Sales (1,066,201) 9,750 (1,056,451) (967,821) 1,690 (966,131) (10.2%) (9.3%) Gross Margin 726,755 9,750 736,505 629,661 1,690 631,351 15.4% 16.7% % Net revenue 40.5% - 41.1% 39.4% 35.2% - - R&D (87,878) 941 (86,937) (88,448) 769 (87,679) 0.6% 0.8% SG&A (319,425) 29,579 (289,846) (301,815) 11,346 (290,469) (5.8%) 0.2% Operating Expenses (407,303) 30,520 (376,783) (390,262) 12,115 (378,147) (4.4%) 0.4% (2,420) - (2,420) 7,518 7,518 (132.2%) (132.2%) OPERATING RESULT (EBIT) 317,032 40,270 357,302 246,917 13,805 260,722 28.4% 37.0% % Net revenue 17.7% - 19.9% 15.5% 16.3% - - Financial Result (197,613) 39,336 (158,277) (150,936) (150,936) (30.9%) (4.9%) - - - (65) (65) 100.0% 100.0% PROFIT BEFORE TAX 119,419 79,606 199,025 95,916 13,805 109,722 24.5% 81.4% % Net revenue 6.7% - 11.1% 5.3% 6.1% - - Income Tax Expense (37,441) (17,760) (55,201) (5,578) (3,451) (9,029) (571.2%) (511.4%) % of pre-tax income 31.4% - 27.7% 4.7% 7.6% - - CONSOLIDATED PROFIT 81,978 61,846 143,824 90,338 10,354 100,693 (9.3%) 42.8% Results Attributable to Non-Controlling Interests (30,287) (1,903) (32,190) (34,464) (183) (34,647) 12.1% 7.1% GROUP PROFIT 51,691 59,943 111,634 55,875 10,171 66,046 (7.5%) 69.0% % Net revenue 2.9% - 6.2% 3.1% 2.5% Q3 2024 % vs PY Share of Results of Equity Accounted Investees Share of Results of Equity Accounted Investees - Core Activities Grifols GrifolsGrifols Q3 2023

- 26 - Q3 2024 Results P&L | 2024 YTD In thousands of euros Reported One-offs Reported excl. One-offs Reported One-offs Reported excl. One-offs Reported Reported excl. One-offs Net Revenue 5,236,569 - 5,236,569 4,822,427 (18,830) 4,803,597 8.6% 9.0% Cost of Sales (3,208,525) 43,043 (3,165,482) (3,030,663) 28,689 (3,001,974) (5.9%) (5.4%) Gross Margin 2,028,044 43,043 2,071,087 1,791,764 9,859 1,801,623 13.2% 15.0% % Net revenue 38.7% - 39.6% 37.2% 34.4% R&D (269,035) 2,542 (266,493) (281,697) 5,810 (275,887) 4.5% 3.4% SG&A (985,812) 77,241 (908,571) (1,018,049) 133,496 (884,553) 3.2% (2.7%) Operating Expenses (1,254,847) 79,783 (1,175,064) (1,299,746) 139,306 (1,160,440) 3.5% (1.3%) 46,959 (5,618) 41,341 35,047 - 35,047 34.0% 18.0% OPERATING RESULT (EBIT) 820,156 117,208 937,364 527,065 149,165 676,230 55.6% 38.6% % Net revenue 15.7% - 17.9% 10.9% 14.1% Financial Result (586,702) 86,099 (500,603) (425,054) - (425,054) (38.0%) (17.8%) - - - (927) - (927) 100.0% 100.0% PROFIT BEFORE TAX 233,455 203,307 436,761 101,085 149,165 250,251 131.0% 74.5% % Net revenue 4.5% - 8.3% 1.9% 4.8% Income Tax Expense (104,434) (18,662) (123,096) (15,697) (37,317) (53,014) (565.3%) (132.2%) % of pre-tax income 44.7% - 28.2% 6.7% 22.7% CONSOLIDATED PROFIT 129,021 184,645 313,665 85,387 111,848 197,236 51.1% 59.0% Results Attributable to Non-Controlling Interests (41,069) (8,515) (49,584) (99,612) 3,981 (95,631) 58.8% 48.2% GROUP PROFIT 87,952 176,130 264,081 (14,224) 115,829 101,606 718.3% 159.9% % Net revenue 1.7% - 5.0% (0.3%) 2.5% Share of Results of Equity Accounted Investees - Core Activities Share of Results of Equity Accounted Investees Grifols Combined % vs PY Grifols Combined Grifols Combined 2024 YTD 2023 YTD

- 27 - Q3 2024 Results Cash Flow | Q3 2024 In thousands of euros Reported Reported Reported Reported Group Profit 51,691 55,875 -7% Depreciation and Amortization 108,364 108,076 0% Net Provisions 4,453 19,269 -77% Other Adjustments and Other Changes in Working Capital 158,008 78,721 101% Change in Operating Working Capital (22,906) (112,779) 80% Changes in Inventories 58,900 (137,134) 143% Change in Trade Receivables (19,466) 44,227 -144% Change in Trade Payables (62,340) (19,871) -214% Net Cash Flow From Operating Activities 299,610 149,163 101% Business Combinations and Investments in Group Companies (114,352) (48,705) -135% CAPEX (51,299) (57,195) 10% R&D/Other Intangible Assets (32,949) (20,971) -57% Other Cash Inflow / (Outflow) 2,199 7,868 -72% Net Cash Flow From Investing Activities (196,401) (119,003) -65% Free Cash Flow 103,209 30,159 242% Issue / (Repayment) of Debt (1,563,615) (81,968) -1808% Capital Grants 5,817 34 16957% Other Cash Flows From / (Used in) Financing Activities 1,350 (137) 1089% Net Cash Flow From Financing Activities (1,556,448) (82,070) -1796% Total Cash Flow (1,453,239) (51,911) -2699% Cash and Cash Equivalents at the Beginning of the Period 2,113,220 541,040 291% Effect of Exchange Rate Changes in Cash and Cash Equivalents (15,039) 7,505 -300% Cash and Cash Equivalents at the End of the Period 644,942 496,634 30% Q3 2024 Q3 2023 % vs PY Grifols Grifols Grifols - 27 -

- 28 - Q3 2024 Results Cash Flow | 2024 YTD In thousands of euros Reported Reported Reported Reported Group Profit 87,951 (14,224) 718% Depreciation and Amortization 327,766 336,712 -3% Net Provisions 59,339 95,110 -38% Other Adjustments and Other Changes in Working Capital 110,352 34,023 224% Change in Operating Working Capital (197,858) (382,818) 48% Changes in Inventories (73,982) (324,359) 77% Change in Trade Receivables (109,135) (83,296) -31% Change in Trade Payables (14,741) 24,837 -159% Net Cash Flow From Operating Activities 387,550 68,803 463% Business Combinations and Investments in Group Companies 1,310,779 (48,705) 2791% CAPEX (132,415) (144,508) 8% R&D/Other Intangible Assets (96,200) (61,642) -56% Other Cash Inflow / (Outflow) (17,188) 1,077 -1696% Net Cash Flow From Investing Activities 1,064,976 (253,778) 520% Free Cash Flow 1,452,526 (184,976) 885% Issue / (Repayment) of Debt (1,360,029) 128,496 -1158% Capital Grants 11,516 1,401 722% Other Cash Flows From / (Used in) Financing Activities 16,960 1,968 762% Net Cash Flow From Financing Activities (1,331,553) 131,866 -1110% Total Cash Flow 120,973 (53,110) 328% Cash and Cash Equivalents at the Beginning of the Period 529,577 549,207 -4% Effect of Exchange Rate Changes in Cash and Cash Equivalents (5,608) 537 -1145% Cash and Cash Equivalents at the End of the Period 644,942 496,633 30% Grifols Combined % vs PY Grifols Combined 2024 YTD Grifols Combined 2023 YTD - 28 -

- 29 - Q3 2024 Results Balance Sheet | 2024 YTD In thousands of euros sep-24 dic-23 14,960,381 14,861,087 10,654,352 10,579,562 3,162,439 3,247,123 53,220 421,763 636,877 176,676 453,493 435,962 5,323,263 6,131,016 - 1,089,856 3,455,609 3,482,399 33,695 47,751 973,668 767,259 161,799 140,232 53,550 73,942 644,942 529,577 20,283,644 20,992,103 Cash and Cash Equivalents Goodwill and Other Intangible Assets Property Plant & Equipment Assets Non-Current Assets Total Assets Current Assets Inventories Current Contract Assets Other Current Financial Assets Non-Current Contract Assets Held for Sale Trade and Other Receivables Investments in Equity Accounted Investees Non-Current Financial Assets Other Non-Current Assets Other Current Assets In thousands of euros sep-24 dic-23 7,995,060 7,513,695 119,604 119,604 910,728 910,728 4,068,062 4,040,961 Treasury Stock (145,287) (152,748) 87,952 42,318 308,836 407,513 2,645,165 2,145,320 9,933,009 11,152,965 8,836,252 10,033,604 1,096,757 1,119,360 2,355,575 2,325,443 1,016,882 1,023,614 1,338,693 1,301,829 20,283,644 20,992,103 Other Current Liabilities Total Equity and Liabilities Other Comprehensive Income Non-Controllling Interests No-Current Liabilities Non-Current Financial Liabilities Other Non-Current Liabilities Share Premium Reserves Current Year Earnings Current Liabilities Current Financial Liabilities Capital Equity Liabilities

- 30 - Q3 2024 Results EBIT to EBITDA and EBITDA Adjusted In thousand of euros 317,034 299,321 203,802 255,252 1,075,409 246,917 (108,364) (114,310) (106,139) (113,869) (442,683) (110,093) Reported EBITDA 425,398 413,631 309,941 369,122 1,518,093 357,010 % Net revenue 23.7% 22.8% 19.1% 20.9% 22.4% 22.3% Restructuring costs 21,673 10,095 2,326 19,916 54,009 - Transaction costs 7,882 16,145 15,318 19,590 58,934 13,762 Impairments 787 - - 1,794 2,581 - Biotest Next Level Project 5,113 4,922 16,798 33,100 59,934 - SRAAS One-off - (5,618) - - (5,618) - Other non-recurring items 1,245 1,613 6,020 - 8,877 - Total adjustments 36,700 27,157 40,461 74,400 178,717 13,762 Adjusted EBITDA 462,098 440,788 350,402 443,522 1,696,812 370,772 % Net revenue 25.8% 24.2% 21.6% 25.1% 25.0% 23.2% Q3 2024 Q1 2024 Q4 2023 Q3 2023Q2 2024 Q3 2024 LTM Depreciation & Amortization OPERATING RESULT (EBIT) - 30 -

- 31 - Q3 2024 Results Leverage Ratio as per Credit Agreement In millions of euros except ratio. Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Non-Current Financial Liabilities 8,836 8,752 9,650 10,034 10,413 Non-recurrent Lease Liabilities (IFRS16) (969) (1,025) (1,026) (1,004) (1,042) Current Financial Liabilities 1,017 2,757 1,745 1,023 764 Recurrent Lease Liabilities (IFRS16) (111) (109) (111) (107) (111) Cash and Cash Equivalents (645) (2,113) (449) (530) (497) Net Financial Debt as per Credit Agreement 8,128 8,262 9,811 9,416 9,527 In millions of euros except ratio. LTM Q3'24 LTM Q2'24 LTM Q1'24 FY 2023 LTM Q3'23 OPERATING RESULT (EBIT) 1,075 1,005 934 781 676 Depreciation & Amortization (443) (444) (441) (458) (468) Reported EBITDA 1,518 1,450 1,375 1,239 1,144 IFRS 16 (113) (110) (104) (102) (103) Restructuring costs 57 34 24 159 165 Transaction costs 59 65 59 48 31 Cost savings, operating improvements and synergies on a "run rate" 146 136 131 134 126 Other one-offs (62) (75) (43) (7) 24 Total adjustments 87 50 66 232 243 Adjusted EBITDA LTM as per Credit Agreement 1,605 1,500 1,442 1,471 1,387 Leverage Ratio as per Credit Agreeement 5.1x 5.5x 6.8x 6.4x 6.9x

- 32 - Q3 2024 Results Leverage Ratio as per Consolidated EBITDA and Net Debt as per Balance Sheet In millions of euros except ratio. Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Non-Current Financial Liabilities 8,836 8,752 9,650 10,034 10,413 Current Financial Liabilities 1,017 2,757 1,745 1,023 764 Cash and Cash Equivalents (645) (2,113) (449) (530) (497) Net Financial Debt 9,208 9,396 10,947 10,527 10,680 In millions of euros except ratio. LTM Q3'24 LTM Q2'24 LTM Q1'24 FY 2023 LTM Q3'23 OPERATING RESULT (EBIT) 1,077 1,005 934 781 676 Depreciation & Amortization (441) (444) (441) (458) (468) Reported EBITDA 1,518 1,450 1,375 1,239 1,144 Leverage Ratio Reported 6.1x 6.5x 8.0x 8.5x 9.3x

- 33 - Q3 2024 Results NCI Contributions In thousand of euros GDS Biotest BPC Haema Profit after tax from continuing operations 113,203 (87,629) 49,564 3,846 Income tax expense (47,111) 15,714 3,840 (8,440) Financial result 67,933 (37,329) 6,981 7,805 Amortisation and depreciation (47,370) (54,396) (8,151) (8,381) Consolidated EBITDA 139,751 (11,617) 46,894 12,862 Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (2,381) (8,188) (5,514) (4,644) Restructuring costs 5,697 - 202 0 Other non-recurring items - 10,400 - - Consolidated EBITDA under Credit Agreement 143,066 (9,405) 41,581 8,219 % of non-controlling interest 45% 30% 100% 100% Consolidated EBITDA according to Credit Agreement non-controlling interest 64,380 (2,805) 41,581 8,219 Cash and cash equivalents (733) (24,656) (6,879) (18,992) Financial assets/liabilities with Grifols (1,032,122) 334,393 - - Leasing liabilities (leases of real estate of plasma donation centres) 12,943 58,208 55,894 12,669 Loans and other financial liabilities 524 72,130 - - Total Balance Sheet Net Debt (1,019,389) 440,075 49,015 (6,323) Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (12,943) (58,208) (55,894) (12,669) Total Net Financial Debt according to Credit Agreement (1,032,332) 381,867 (6,879) (18,992) Total Net Financial Debt according to Credit Agreement non-controlling interest (464,549) 113,873 (6,879) (18,992) LTM Q3 2024

- 34 - Q3 2024 Results FCF Before Extraordinary Items In millions of euros Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 EBITDA Adjusted 462 441 350 444 371 Changes in working capital (23) 164 (339) (23) (113) CAPEX (51) (43) (38) (80) (57) R&D and IT (33) (41) (22) (24) (21) Taxes (32) (59) (4) (91) (37) Interests (55) (233) (106) (129) (111) Others 15 (32) (66) (49) 64 FCF Before Extraordinary Items 282 196 (225) 48 96 Extraordinary Growth CAPEX (114) (119) (23) (19) (48) Restructuring and transaction costs (41) (20) (5) (20) (19) Free Cash Flow 127 57 (253) 9 30

- 35 - Q3 2024 Results Net Revenue Reconciliation at cc | Q3 2024 In thousands of euros Q3 2024 Q3 2023 % Var Reported Net Revenues 1,792,956 1,597,481 12.2% Variation due to Exchange Rate Effects 2,040 Net Revenues at Constant Currency 1,794,996 1,597,481 12.4% In thousands of euros Q3 2024 Q3 2023 % Var Reported Biopharma Net Revenues 1,532,745 1,367,663 12.1% Variation due to Exchange Rate Effects 33 Reported Biopharma Net Revenues at Constant Currency 1,532,778 1,367,663 12.1% In thousands of euros Q3 2024 Q3 2023 % Var Reported Diagnostic Net Revenues 156,292 156,283 0.0% Variation due to Exchange Rate Effects 2,030 Reported Diagnostic Net Revenues at Constant Currency 158,322 156,283 1.3% In thousands of euros Q3 2024 Q3 2023 % Var Reported Bio Supplies Net Revenues 53,698 36,056 48.9% Variation due to Exchange Rate Effects (99) Reported Bio Supplies Net Revenues at Constant Currency 53,599 36,056 48.7% In thousands of euros Q3 2024 Q3 2023 % Var Reported Others & Intersegments Net Revenues 50,221 37,479 34.0% Variation due to Exchange Rate Effects 76 Reported Other & Intersegments Net Revenues at Constant Currency 50,297 37,479 34.2% In thousands of euros Q3 2024 Q3 2023 % Var Reported U.S. + Canada Net Revenues 1,044,035 970,208 7.6% Variation due to Exchange Rate Effects (3,816) Reported U.S. + Canada Net Revenues at Constant Currency 1,040,219 970,208 7.2% In thousands of euros Q3 2024 Q3 2023 % Var Reported EU Net Revenues 359,448 289,423 24.2% Variation due to Exchange Rate Effects (53) Reported EU Net Revenues at Constant Currency 359,395 289,423 24.2% In thousands of euros Q3 2024 Q3 2023 % Var Reported ROW Net Revenues 389,474 337,850 15.3% Variation due to Exchange Rate Effects 5,909 Reported ROW Net Revenues at Constant Currency 395,383 337,850 17.0%

- 36 - Q3 2024 Results Net Revenue Reconciliation at cc | 2024 YTD In thousands of euros 2024 YTD 2023 YTD % Var Reported Net Revenues 5,236,568 4,822,427 8.6% Variation due to Exchange Rate Effects 23,726 Net Revenues at Constant Currency 5,260,294 4,822,427 9.1% In thousands of euros 2024 YTD 2023 YTD % Var Reported Biopharma Net Revenues 4,455,100 4,065,878 9.6% Variation due to Exchange Rate Effects 14,766 Reported Biopharma Net Revenues at Constant Currency 4,469,866 4,065,878 9.9% In thousands of euros 2024 YTD 2023 YTD % Var Reported Diagnostic Net Revenues 478,835 497,772 (3.8%) Variation due to Exchange Rate Effects 8,381 Reported Diagnostic Net Revenues at Constant Currency 487,216 497,772 (2.1%) In thousands of euros 2024 YTD 2023 YTD % Var Reported Bio Supplies Net Revenues 163,261 118,670 37.6% Variation due to Exchange Rate Effects (121) Reported Bio Supplies Net Revenues at Constant Currency 163,140 118,670 37.5% In thousands of euros 2024 YTD 2023 YTD % Var Reported Others & Intersegments Net Revenues 139,371 140,106 (0.5%) Variation due to Exchange Rate Effects 700 Reported Other & Intersegments Net Revenues at Constant Currency 140,071 140,106 0.0% In thousands of euros 2024 YTD 2023 YTD % Var Reported U.S. + Canada Net Revenues 3,007,232 2,893,072 3.9% Variation due to Exchange Rate Effects 6,590 Reported U.S. + Canada Net Revenues at Constant Currency 3,013,822 2,893,072 4.2% In thousands of euros 2024 YTD 2023 YTD % Var Reported EU Net Revenues 1,109,757 916,955 21.0% Variation due to Exchange Rate Effects (164) Reported EU Net Revenues at Constant Currency 1,109,593 916,955 21.0% In thousands of euros 2024 YTD 2023 YTD % Var Reported ROW Net Revenues 1,119,579 1,012,400 10.6% Variation due to Exchange Rate Effects 17,300 Reported ROW Net Revenues at Constant Currency 1,136,879 1,012,400 12.3%

- 37 - Q3 2024 Results Investor Relations

& Sustainability + 34 93 571 02 21 investors@grifols.com sustainability@grifols.com inversores@grifols.com sostenibilidad@grifols.com